Press release: agreement to deliver orthopaedic treatments using stem cell therapies
9 February 2007
UCL Business PLC and the Royal National Orthopaedic Hospital NHS Trust (RNOH) have signed an agreement with Sewon Cellontech (SC) of South Korea to collaborate on new laboratories that will develop clinical cell therapeutic treatments for cartilage repair and bone fracture healing.
The techniques use stem cells derived from the patient's own bone marrow and cartilage tissue with the potential to alleviate the need for radical surgery.
Read the full press release.
Image 1: (l-r) Mike Spyer, Vice Provost (Enterprise), UCL ; Chang Cheong-Ho, Chairman, Sewon Cellontech Co. Ltd; and Donald Hoodless, Chairman, RNOH
Image 2: (l-r) Cengiz Tarhan, Managing Director, UCL Business PLC; Martin Ferguson-Pell, Director of Research & Development, RNOH; Henry Kwon, Vice President, Sewon Cellontech Co. Ltd.; Chang Cheong-Ho, Chairman, Sewon Cellontech Co. Ltd.; Andrew Woodhead, Chief Executive, RNOH; Howard Klevens, International Consultant, Sewon Cellontech Co. Ltd.; Mike Spyer, Vice Provost (Enterprise), UCL; and UCL President and Provost Professor Malcolm Grant